IDH mutations define a subgroup of diffuse gliomas—including WHO grade 3 and 4 astrocytomas—that present at younger ages and confer improved survival relative to IDH wild-type glioblastomas [5–10]. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).